Literature DB >> 9682269

A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502).

K Nunoya1, T Yokoi, K Kimura, K Inoue, T Kodama, M Funayama, K Nagashima, Y Funae, C Green, M Kinoshita, T Kamataki.   

Abstract

The S-oxidation of (4)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502) and the 7-hydroxylation of coumarin are primarily catalyzed by cytochrome P450 2A6 (CYP2A6). The activities of SM-12502 S-oxidase and coumarin 7-hydroxylase were investigated with liver microsomes from 20 human individuals. Liver microsomes from individual H16 showed the lowest activities of both enzymes. The expression of CYP2A6 protein was not detectable in liver microsomes from individuals H4, H5, H7, H8, H12 and H16. CYP2A6 mRNA was hardly detectable in the liver of the individual H16. A new SacI-restriction fragment length polymorphism showing the lack of a 2.6 kb fragment was found in two of forty genomic DNA preparations from individuals H16 and No. 594, using CYP2A6 cDNA as a probe. This deletional 2.6 kb fragment was isolated from a genomic library prepared from one individuals showing normal coumarin 7-hydroxylase activity and was sequenced. This fragment contained a CYP2A6 gene region from 319 bp upstream of a putative exon 6 to a SacI site in exon 9, indicating that this region was deleted in the two individuals in this study. We also demonstrated by polymerase chain reaction analysis that the exon 8 of CYP2A6 gene was deleted in individuals H16 and No. 594. These results indicate that the reduced activity of SM-12502 S-oxidase and no activity of coumarin 7-hydroxylase are caused by the lack of CYP2A6 mRNA and CYP2A6 protein caused by the CYP2A6 gene deletion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9682269     DOI: 10.1097/00008571-199806000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  11 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 2.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Associations of CYP2A6 genotype with smoking behaviors in southern China.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Qian Zhou; Peng Ding; Yan-Hui He; Xue-Qing Yu; Wei Chen; Casey Crump; Xiao-Zhong Wen; Wei-Qing Chen
Journal:  Addiction       Date:  2011-05       Impact factor: 6.526

Review 4.  The genetics of nicotine dependence: relationship to pancreatic cancer.

Authors:  Stewart L MacLeod; Parimal Chowdhury
Journal:  World J Gastroenterol       Date:  2006-12-14       Impact factor: 5.742

5.  Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema.

Authors:  N Minematsu; H Nakamura; M Iwata; H Tateno; T Nakajima; S Takahashi; S Fujishima; K Yamaguchi
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

6.  Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Authors:  David W Haas; Awewura Kwara; Danielle M Richardson; Paxton Baker; Ioannis Papageorgiou; Edward P Acosta; Gene D Morse; Michael H Court
Journal:  J Antimicrob Chemother       Date:  2014-04-11       Impact factor: 5.790

7.  Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis.

Authors:  Zheng-Bing Liu; Jun Shu; Li-Ping Wang; Cheng Jin; Zhi-Xia Lou
Journal:  Mol Biol Rep       Date:  2013-06-04       Impact factor: 2.316

Review 8.  Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.

Authors:  Riju Ray; Rachel F Tyndale; Caryn Lerman
Journal:  J Neurogenet       Date:  2009-01-23       Impact factor: 1.250

Review 9.  Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer.

Authors:  A Hirvonen
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

10.  A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.

Authors:  Makoto Murata; Edus H Warren; Stanley R Riddell
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.